Board of Directors

Karel Boone

Chairman, Member of the Audit Committee and Member of the Remuneration and Nomination Committee

Commercial Engineer (KUL), Karel Boone started in 1966 as an executive member of the Board of Directors of Lotus Bakeries (Lotus Biscuits at this time) and became CEO in 1974 when Lotus Biscuits merged with Corona. He was also Executive Chairman of the Board of Directors from 1992 until 2006 when he became non-Executive Chairman of the Board of Directors. He is a member of the following Boards of Directors: Axa Belgium, Banque Degroof, Compagnie du Bois Sauvage and Vandemoortele (Chairman). He is a member of the Corporate Governance Committee for Belgian listed companies. He is active in professional organizations : he has been Chairman of the Federation of Belgian Companies.

Countess Diego du Monceau

Vice-Chair and Chair of the Remuneration and Nomination Committee

Married and mother of three children, Evelyn du Monceau has graduated in Applied Economics from the Catholic University of Louvain UCL in Belgium.

She followed courses in International Relations at the Kennedy School of Harvard University and in Soil Science, Animal Science and Zoology at the Agricultural and Technical College of Farmingdale (N.Y.).

Evelyn du Monceau is a member of the Board of UCB since 1984 and has been elected Vice-Chair of the Board since 2006. She also is Chair of the Remuneration and Nomination Committee since 2006. She is a member of the Board of Directors of Financière de Tubize and of Solvac S.A.

Dr Roch Doliveux

Chief Executive Officer and Chairman of the Executive Committee

Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA from INSEAD (France) with distinction.

He joined the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in France, and then at Schering-Plough Corporation in various positions, including President of Schering-Plough International. Then, Roch Doliveux joined the Pierre Fabre group as Chief Executive Officer of Pierre Fabre Pharmaceuticals.

Roch Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, a member of the Board of Stryker Corporation, a US listed company, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, WELBIO (Walloon Institute for Life Lead Sciences), the INSEAD International Council, the Science & Business Innovation and the Caring Entrepreneurship Fund (King Baudouin Foundation).

Albrecht De Graeve

Independant Director and Member of the Audit Committee

Bert De Graeve (1955) is CEO of the Bekaert Group since May 2006. From 2002 until May 2006 he was CFO and company secretary of the Group.
He started his career in 1980 with Arthur Andersen & Co and joined Alcatel Bell in 1982. In 1991 he became General Manager Shanghai Bell Telephone Equipment Mfg. Cy in Shanghai. In 1994 he was appointed Vice President, Director Operations, Alcatel Trade International and later Director International Affairs, Alcatel Alsthom in Paris.
In 1996 he became Managing Director of the Flemish Public Radio & TV Broadcaster (VRT).  
Bert De Graeve holds a master in Law from the University of Gent (1980) and studied Financial Management at IPO (Antwerp). He became Master in Tax Management at VLEKHO (Brussels).
Bert De Graeve is Member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), President of the Flanders-China Chamber of Commerce,
Member of the Advisory Board of the Conference Board China Center for Economics and Business in Beijing,  Member of the Board of the Concours Reine Elisabeth and Senior Member of the Conference Board New York.

Dr Peter Fellner

Independent Director and Member of the Scientific Committee

Peter Fellner (1943), who is British, is currently Chairman of the medical device companies, Consort Medical Plc and Optos Plc.  He also serves as Chairman of the U.K. biotechnology companies, Vernalis plc and Astex Therapeutics Ltd, and as a Director of the European bioscience companies, Biotie Therapies Corp and Evotec AG. He was previously Chairman of Celltech Group plc, having served as its CEO from 1990 to 2003. He oversaw its development into the U.K.'s largest biotechnology company, and a FTSE 100 constituent, until its acquisition by UCB in 2004. Before joining Celltech, he served as CEO of Roche U.K., from 1986 to 1990. From 1984 to 1986 he was Director of the Roche U.K. Research Centre.

Norman J. Ornstein

Independent Director

Norman J-Ornstein is a resident scholar at the American Enterprise Institute for Public Policy Research based in Washington D.C., USA, and counsels government campaign commissions. He also serves as an election analyst for CBS News and writes in several US newspapers in parallel to having published several books related to US politics. Mr Ornstein has a B.A. from the University of Minnesota, from which he also received an honorary Doctor of Laws degree, and a M.A. and PhD from the University of Michigan. He served as a member the Board of the Public Broadcasting Service (PBS) and is currently on the Board of Directors of the Campaign Legal Center, as well as of the Board of Trustees of the US Capitol Historical Society.

Jean-Pierre Kinet

Independent Director and Member of the Scientific Committee

Jean-Pierre Kinet holds a medical degree (MD) from the University of Liège. He is currently a full Professor of Pathology at Harvard Medical School and at one of the Harvard affiliated hospitals, the Beth Israel Deaconess Medical Center in Boston. He is a member of numerous Harvard, US and International committees such as various National Institutes of Health (NIH) expert panels and the International Strategic Committee of Biowin (Health Cluster of Wallonia). He has a large experience in the research and development of novel therapies and is a board member of several biotechnology companies.

Thomas Leysen

Independent Director and Member of the Remuneration and Nomination Committee

Thomas Leysen, born in 1960, is Chairman of Umicore since November 19th, 2008. He was Chief Executive Officer of Umicore from May 2000 until November 19th, 2008.

He holds a Master of Law Degree from the University of Leuven (Belgium).
He started his career in the maritime business in Hamburg, London and Tokyo. From 1983 till 1988, he managed the Transcor group, which he built into an international oil and coal trading company with activities in Europe, America and Asia.
He joined Umicore in 1993 as member of the Executive Committee, and successively managed several industrial divisions. He became Executive Vice President of the company in 1998.
Thomas Leysen is also Chairman of the Board of Corelio, Belgium's largest newspaper-publishing group, member of the Board of CMB (Compagnie Maritime Belge), UCB, Norddeutsche Affinerie, Etex Group as well as member of the Supervisory Board of Bank Metzler in Frankfurt.
He is Chairman of FEB - VBO (Federation of Belgian Entreprises) and past Chairman of Eurométaux (the European metals industry federation). He is also President of the BJA (Belgium-Japan Association).
He is a member of the Trilateral Commission and of the European Round Table of Industrialists (ERT).
In the cultural sphere, he is member of the Board of trustees of the Rubens House Museum in Antwerp and is Chairman of the Art Purchase Fund of the Fondation Roi Baudouin.

Gerhard N. Mayr

Independent Director, Member of the Audit Committee and Member of the Remuneration and Nomination Committee

A native of Austria, Gerhard Mayr received a master's degree in chemical engineering from the Swiss Federal Institute of Technology (Zurich, Switzerland) in 1969, and a master of business administration degree from Stanford University in 1972. In March 2004, he retired as executive vice president of pharmaceutical operations at Eli Lilly & Company after 32 years of service. He had been responsible for global pharmaceutical operations and sales and marketing worldwide at Lilly - a leading innovation-driven corporation. Gerhard Mayr is past chairman of both the International Executive Committee and the Europe Committee of the Pharmaceutical Research Manufacturers of America. He was a board member of the European Federation of the Pharmaceutical Industry from 1995-1997 and 2000-2002. Gerhard Mayr is a Member of the Board of Lonza Group Ltd.

Sir Tom McKillop

Independent Director and Member of the Remuneration and Nomination Committee

Tom McKillop was born in Ayrshire, Scotland in 1943 and educated at Irvine Royal Academy, Glasgow University and Centre de Mecanique Ondulatoire Appliquee (Paris). He joined ICI's Corporate Research Laboratory at Runcorn in 1969 and his research interests ranged from synthetic chemistry to quantum mechanics and molecular biology. In 1975 he moved to ICI Pharmaceuticals Division and held a number of increasingly senior Research and Development positions until his appointment in1989 as Technical Director and Deputy Chairman of ICI Pharmaceuticals, a role in which he had global responsibility for Research, Development, Medical and Production. In 1994, he was appointed Chief Executive Officer of Zeneca Pharmaceuticals - Zeneca having demerged from ICI in 1993 - and, on completion of the merger of Astra and Zeneca in April 1999, he became Chief Executive of AstraZeneca PLC, a position he held until retiring on 31 December 2005. His wider industry activities included periods as Chairman of the British Pharma Group, President of the European Federation of Pharmaceutical Industries and Associations, Chairman of the Pharmaceutical Industry Task Force, and as a member of The European Round Table of Industrialists and the European Financial Round Table. Currently Sir Tom is president of The Science Council and a non-executive director of Almirall Prodesfarma SA. He has previously served as Chairman of the Royal Bank of Scotland, and as a non-executive director of BP plc, Amersham International plc (now GE Healthcare) and Lloyds TSB plc. During his career Sir Tom has received many scholarly awards and fellowships and was knighted in 2002 for services to the pharmaceutical industry.

Count Arnoud de Pret Roose de Calesberg

Director and Chairman of the Audit Committee

Count Arnoud de Pret (1944), Director, Chairman of the Audit Committee, consultant. Commercial Engineer from UCL (Louvain). He started his career as Credit Officer with Morgan Guaranty Trust of New-York (Brussels and Antwerp) in 1971. He became Treasurer and Corporate Finance Manager Cockerill (Liège) in 1978. He joined UCB (Brussels) in 1981 as Chief Financial Officer and Member of the Executive Committee. He became in 1990, Treasurer and Corporate Finance Manager at Société Générale de Belgique before joining Umicore in 1991 as Chief Financial Officer and Member of the Management Committee until May 2000.
He is Director and Member of the Audit Committee of InBev, Umicore, Sibelco, Delhaize Group and serves as member of the Supervisory Board of NYSE Euronext.

Alexandre Van Damme

Director

Alexandre Van Damme holds a degree in business economics and graduated in 1985 from the Solvay Business School (Brussels).  He joined the beer industry early and held various functions within Belgium based Interbrew until 1991.  He joined the Board of Directors of Anheuser-Busch InBev (previously Interbrew and Inbev) in 1992 and is a Board member of InBev-Baillet Latour (non profit organization) and various Private Family owned companies.  He is also a member of the Insead International Council and the Solvay Business School Consultative Counsel.

Mrs Jean van Rijckevorsel

Director

She is married and mother of two children. Mrs Jean van Rijckevorsel is a member of the Board of Directors of privately owned investment companies.

Gaëtan van de Werve

Director

Doctor of Law (KUL), he also holds an MBA from Vlerick Management School (RUG) in 1972.
He joined Petrofina SA in 1973 where he held various management responsibilities in the areas of supply, sales and marketing. He was the managing director of Sigma Paints (Thailand) from 1983 to 1985.
In 1992, he joined the European Petroleum Industry Association (EUROPIA) as executive officer, responsible for Environment, tax and legal.
In 1996, he joined the Belgian Oil Industry Association as Secretary-general.
Gaëtan van de Werve is not member of the Board of another listed company.